Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy of the Combination of Antioxidants Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With Polycystic Ovary Syndrome: A Prospective Randomized Study.

NCT05340634 is registered in ClinicalTrials.gov with Margan Biotech as lead sponsor.

NCT NCT05340634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05340634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy of the Combination of Antioxidants Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With Polycystic Ovary Syndrome: A Prospective Randomized Study.
Lead sponsor
Margan Biotech
Phase
Phase 4
Overall status
Completed
Start date
April 20, 2020
Completion date
February 2, 2022
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

polycystic ovary syndrome